Consequently, olaparib is mainly investigated in the context of BRCA-deficient cancer types and has already been approved by the European Medicines Agency (EMA) and US FDA for the treatment of recurrent ovarian cancer in BRCA1/2-mutated women [50]. This evidence concerns the gene BRCA1 and ovarian cancer.